EUVIMEDEUVIMED entdecken
Crossref

CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?

Raquel Ron iD, Elena Moreno, Javier Martínez-Sanz, Fátima Brañas, Talía Sainz, Santiago Moreno iD, Sergio Serrano-Villar iD

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Raquel Ron und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Universitario Ramón y Cajal and Investigación Sanitaria Ramón y Cajal (IRYCIS), Madrid, Spain. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, ERDF, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last decade, studies in persons with HIV (PWH) on antiretroviral therapy (ART) have shed light on the significance of persistently high CD8 counts and low CD4/CD8 ratios. A low CD4/CD8 ratio reflects increased immune activation and is associated with an increased risk of severe non-AIDS events. As a result, many clinicians now believe that the CD4/CD8 ratio can help in HIV monitoring, and many researchers now report it as an efficacy marker in interventional studies. However, the topic is more complex. Recent studies have not yielded unanimous conclusions on the ability of the CD4/CD8 ratio to predict adverse outcomes, and only some clinical guidelines recommend monitoring it. Knowledge gaps remain on the best cutoff points, associated clinical events, effects of treatments, and how the CD4/CD8 ratio could improve decision making in the clinic. Here, we critically review the literature, identify knowledge gaps, and discuss the role of the CD4/CD8 ratio as a marker for HIV monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHumansHIVCD4-CD8 RatioCD8-Positive T-LymphocytesCD4 Lymphocyte CountViral Load

Stichwörter der Autor:innen

CD4/CD8 ratioCD8 countsHIV monitoringmortalitynon-AIDS events

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hospital Universitario Ramón y Cajal and Investigación Sanitaria Ramón y Cajal (IRYCIS), Madrid, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Immunovirology Laboratory, Hospital Universitario Ramón y Cajal and IRYCIS, Madrid, Spain.
  • Department of Geriatrics, Hospital Universitario Infanta Leonor, Madrid, Spain.
  • Department of Pediatric Infectious Diseases, Hospital Universitario La Paz, Madrid, Spain.
  • Department of Medicine, Universidad de Alcalá, Madrid, Spain.

ORCID-Profile: Raquel Ron, Santiago Moreno, Sergio Serrano-Villar

Förderung

  • Instituto de Salud Carlos III
  • ERDF
  • European Union

Zitieren

APA

Ron, R., Moreno, E., Martínez-Sanz, J., Brañas, F., Sainz, T., Moreno, S., & Serrano-Villar, S. (2023). CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad136

Vancouver

Ron R, Moreno E, Martínez-Sanz J, Brañas F, Sainz T, Moreno S, et al. CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad136

BibTeX
@article{Ron2023,
  author = {Ron, Raquel and Moreno, Elena and Martínez-Sanz, Javier and Brañas, Fátima and Sainz, Talía and Moreno, Santiago and Serrano-Villar, Sergio},
  title = {CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad136}
}
Kostenlos starten →